Eradicating cancer cells: struggle with a chameleon

Jiabo Di; Tjitske Duiveman-de Boer; Carl G. Figdor; Ruurd Torensma

doi:10.18632/oncotarget.222

Oncotarget

Oncotarget (a primarily oncology-focused, peer-reviewed, open access journal) aims to maximize research impact through insightful peer-review; eliminate borders between specialties by linking different fields of oncology, cancer research and biomedical sciences; and foster application of basic and clinical science.

Its scope is unique. The term "oncotarget" encompasses all molecules, pathways, cellular functions, cell types, and even tissues that can be viewed as targets relevant to cancer as well as other diseases. The term was introduced in the inaugural Editorial, Introducing Oncotarget.

As of January 1, 2022, Oncotarget has shifted to a continuous publishing model. Papers will now be published continuously within yearly volumes in their final and complete form and then quickly released to Pubmed.

Subscribe to receive alerts once a paper has been published by Oncotarget.

Impact Journals, LLC is the publisher of Oncotarget: www.impactjournals.com.

Impact Journals is a member of the Wellcome Trust List of Compliant Publishers.

Impact Journals is a member of the Society for Scholarly Publishing.

On December 23, 2022, Oncotarget server experienced a DDoS attack. As a result, Oncotarget site was inaccessible for a few hours. Oncotarget team swiftly dealt with the situation and took it under control. This malicious action will be reported to the FBI.

Research Perspectives:

Eradicating cancer cells: struggle with a chameleon

Jiabo Di, Tjitske Duiveman-de Boer, Carl G. Figdor and Ruurd Torensma _

PDF | HTML | How to cite

Oncotarget. 2011; 2:99-101. https://doi.org/10.18632/oncotarget.222

Metrics: PDF 1995 views | HTML 2918 views | ?

Abstract

Jiabo Di, Tjitske Duiveman-de Boer, Carl G. Figdor and Ruurd Torensma

^*Department of Tumorimmunology, Radboud University Nijmegen Medical Centre, Nijmegen, The Netherlands

Received: February 24, 2011; Accepted: February 28, 2011; Published: February 28, 2011;

Correspondence:

Ruurd Torensma, e-mail:

Abstract

Eradication of cancer stem cells to abrogate tumor growth is a new treatment modality. However, like normal cells cancer cells show plasticity. Differentiated tumor stem cells can acquire stem cell properties when they gain access to the stem cell niche. This indicates that eradicating of stem cells (emptying of the niche) alone will not lead to eradication of the tumor. Treatment should be directed to cancer stem cells ànd more mature cancer cells.

All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.
PII: 222

Publication Alerts

Research Perspectives:

Eradicating cancer cells: struggle with a chameleon

Abstract